Stereotactic body radiotherapy for hepatocellular carcinoma: meta-analysis and International Stereotactic Radiosurgery Society practice guidelines.

[1]  B. Daniele,et al.  Role of Etiology in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Counterfactual Event-Based Mediation Analysis , 2023, Cancers.

[2]  B. Diamond,et al.  Approach to Stereotactic Body Radiotherapy for the Treatment of Advanced Hepatocellular Carcinoma in Patients with Child-Pugh B-7 Cirrhosis , 2022, Current treatment options in oncology.

[3]  2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma , 2022, Clinical and molecular hepatology.

[4]  Young Don Kim,et al.  Stereotactic body radiotherapy versus radiofrequency ablation as initial treatment of small hepatocellular carcinoma , 2022, European journal of gastroenterology & hepatology.

[5]  J. Bibault,et al.  Stereotactic Body Radiation Therapy for the Management of Hepatocellular Carcinoma: Efficacy and Safety , 2022, Cancers.

[6]  T. Stanescu,et al.  Stereotactic body radiation therapy for hepatocellular carcinoma: From infancy to ongoing maturity , 2022, JHEP reports : innovation in hepatology.

[7]  N. Chamroonkul,et al.  Treatment Outcomes of Hepatocellular Carcinoma Patients who underwent Stereotactic Body Radiotherapy , 2022, Journal of Health Science and Medical Research.

[8]  K. Ueshima,et al.  Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib , 2021, ESMO open.

[9]  C. Hallemeier,et al.  External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice Guideline. , 2021, Practical radiation oncology.

[10]  C. H. Rim.  Differences in radiotherapy application according to regional disease characteristics of hepatocellular carcinoma , 2021, Journal of liver cancer.

[11]  I. Amit,et al.  NASH limits anti-tumour surveillance in immunotherapy-treated HCC , 2021, Nature.

[12]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. , 2021, Journal of clinical epidemiology.

[13]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[14]  S. Itasaka,et al.  Stereotactic body radiation therapy versus radiofrequency ablation for single small hepatocellular carcinoma: a propensity-score matching analysis of their impact on liver function and clinical outcomes. , 2021, Journal of gastrointestinal oncology.

[15]  H. Liu,et al.  Stereotactic Ablative Radiotherapy For Hepatocellular Carcinoma: A Systematic Review And Meta-Analysis Of Local Control, Survival, And Toxicity Outcomes , 2020 .

[16]  T. Kimura,et al.  Dose-Response Relationship in Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: A Pooled Analysis of an Asian Liver Radiation Therapy Group Study. , 2020, International journal of radiation oncology, biology, physics.

[17]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2020, BMJ.

[18]  Wengang Li,et al.  Stereotactic body radiotherapy versus hepatic resection for hepatocellular carcinoma (≤ 5 cm): a propensity score analysis , 2020, Hepatology International.

[19]  Jong Hoon Kim,et al.  Stereotactic body radiation therapy for small (≤5 cm) hepatocellular carcinoma not amenable to curative treatment: Results of a single-arm, phase II clinical trial , 2020, Clinical and molecular hepatology.

[20]  Yanchun Liang,et al.  Therapeutic outcome and related predictors of stereotactic body radiotherapy for small liver-confined HCC: a systematic review and meta-analysis of observational studies , 2020, Radiation oncology.

[21]  L. Solbiati,et al.  Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective , 2020, The Lancet Gastroenterology & Hepatology.

[22]  Mengzhong Liu,et al.  Stereotactic Body Radiotherapy as a Salvage Therapy after Incomplete Radiofrequency Ablation for Hepatocellular Carcinoma: A Retrospective Cohort Study , 2020, Journal of oncology.

[23]  L. Dawson,et al.  Long term outcomes of stereotactic body radiation therapy for hepatocellular carcinoma without macrovascular invasion. , 2020, European journal of cancer.

[24]  A. Takeda,et al.  Local control by salvage stereotactic body radiotherapy for recurrent/residual hepatocellular carcinoma after other local therapies , 2020, Acta oncologica.

[25]  P. Liang,et al.  Stereotactic Body Radiation Therapy vs. Transarterial Chemoembolization in Inoperable Barcelona Clinic Liver Cancer Stage a Hepatocellular Carcinoma: A Retrospective, Propensity-Matched Analysis , 2020, Frontiers in Oncology.

[26]  T. Kimura,et al.  Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma. , 2020, Journal of hepatology.

[27]  T. Su,et al.  Optimal stereotactic body radiotherapy dosage for hepatocellular carcinoma: a multicenter study , 2020, Radiation oncology.

[28]  S. Yun,et al.  Clinical outcomes of stereotactic body radiation therapy for small hepatocellular carcinoma , 2020, Journal of gastroenterology and hepatology.

[29]  L. Ting,et al.  Effectiveness of stereotactic ablative radiotherapy in patients with advanced hepatocellular carcinoma unsuitable for transarterial chemoembolization , 2019, Therapeutic advances in medical oncology.

[30]  Meei-Shyuan Lee,et al.  Comparison of Stereotactic Body Radiotherapy and Transarterial Chemoembolization for Unresectable Medium-sized Hepatocellular Carcinoma. , 2019, International journal of radiation oncology, biology, physics.

[31]  B. Jereczek-Fossa,et al.  Stereotactic body radiation therapy for early-stage hepatocellular carcinoma – a systematic review on outcome , 2019, Acta oncologica.

[32]  J. Seong,et al.  Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. , 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[33]  B. Erickson,et al.  Stereotactic body radiation therapy for hepatocellular carcinoma: Practice patterns, dose selection and factors impacting survival , 2019, Cancer medicine.

[34]  K. Awai,et al.  Comparison of Stereotactic Body Radiation Therapy Combined With or Without Transcatheter Arterial Chemoembolization for Patients With Small Hepatocellular Carcinoma Ineligible for Resection or Ablation Therapies , 2018, Technology in cancer research & treatment.

[35]  M. Abecassis,et al.  AASLD guidelines for the treatment of hepatocellular carcinoma , 2018, Hepatology.

[36]  Alan D. Lopez,et al.  The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level , 2017, JAMA oncology.

[37]  A. Niemierko,et al.  Gallbladder toxicity and high-dose ablative-intent radiation for liver tumors: Should we constrain the dose? , 2017, Practical radiation oncology.

[38]  L. Bolondi,et al.  Non-transplant therapies for patients with hepatocellular carcinoma and Child-Pugh-Turcotte class B cirrhosis. , 2017, The Lancet. Oncology.

[39]  D. Taussky,et al.  Stereotactic Body Radiotherapy for Inoperable Liver Tumors: Results of a Single Institutional Experience , 2016, Cureus.

[40]  Mary Feng,et al.  Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  H. Kuo,et al.  Clinical outcomes and prognostic factors of cyberknife stereotactic body radiation therapy for unresectable hepatocellular carcinoma , 2016, BMC Cancer.

[42]  J. Bruix,et al.  Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. , 2016, Gastroenterology.

[43]  Cynthia S. Johnson,et al.  Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotactic body radiation therapy. , 2015, Practical radiation oncology.

[44]  J. Bruix,et al.  Results of laparoscopic radiofrequency ablation for HCC. Could the location of the tumour influence a complete response to treatment? A single European centre experience. , 2015, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[45]  S. Fu,et al.  Charged particle therapy versus photon therapy for patients with hepatocellular carcinoma: a systematic review and meta-analysis. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[46]  M. Scorsetti,et al.  The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT) , 2015, Journal of Cancer Research and Clinical Oncology.

[47]  L. Dawson,et al.  Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[48]  Dong Han Lee,et al.  High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma , 2013, Radiation oncology.

[49]  Zahra Kassam,et al.  Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  Cynthia S. Johnson,et al.  Stereotactic body radiotherapy for primary hepatocellular carcinoma. , 2011, International journal of radiation oncology, biology, physics.

[51]  J. Chung,et al.  Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: A Markov model analysis , 2010, Hepatology.

[52]  M. Miften,et al.  Radiation-associated liver injury. , 2010, International journal of radiation oncology, biology, physics.

[53]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[54]  M Blettner,et al.  Traditional reviews, meta-analyses and pooled analyses in epidemiology. , 1999, International journal of epidemiology.

[55]  J. Bruix,et al.  BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update q , 2022 .

[56]  Andrew Jackson,et al.  Local Control After Stereotactic Body Radiation Therapy for Liver Tumors. , 2018, International journal of radiation oncology, biology, physics.

[57]  P. Tugwell,et al.  The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses , 2014 .

[58]  R. Lencioni,et al.  Local-regional treatment of hepatocellular carcinoma. , 2012, Radiology.

[59]  Stephen W. Raudenbush,et al.  Analyzing effect sizes: Random-effects models. , 2009 .

[60]  I. Lax,et al.  Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. , 1995, Acta oncologica.

[61]  D. Woodfield.  Hepatocellular carcinoma. , 1986, The New Zealand medical journal.